In this study, PGF-MEL had less variability in AUC than previously published for PG-MEL for MM and AL. Toxicities occur more frequently in MM and AL pts with higher than the median AUC, but these differences were not statistically significant, likely due to the small number of pts. Additional toxicity analysis in pts with lymphoma, AML, and MDS will be presented. Longer follow-up is needed to assess disease response and outcomes. This analysis may identify optimal dosing and allow for personalization of therapy and better quality of life after HCT.
Background: Allogeneic donor transplantation (alloHCT) can cure CLL partly by inducing a potent donor-derived graftversus-leukemia (GVL) response. Donor NK cell receptor genetics has been associated with enhanced GVL responses and better survival in AML and lymphoma; however, the influence on post-transplant survival in CLL is unknown. Methods: We identified 573 donor-recipient pairs from 106 centers transplanted between 1995-2014 using unrelated adult donor (UD) grafts. Donor DNA was typed for gene content of 15 individual killer immunoglobulin receptor (KIR) genes. Each donor was assigned a KIR haplotype (A or B) based on the presence of activating and inhibitory KIR genes. To test the donor-recipient NK cell genetic interactions, we examined 4 models: 1. KIR AA vs Bx haplotype (including Cen/Tel and KIR score 1-4), 2. Missing ligand (HLA-C1 vs -C2), 3. Missing Bw4 ligand for inhibitory KIR3DL1, 4. C1/C1 vs C2/2 vs C2/C1 in the presence of activating KIR2DS1. The main objective was to determine the strength of each model to predict relapse and survival. Results: Median age was 56 years (range 21-74). Most patients were not in remission (65%). Most transplants were RIC (77%), 38% applied in vivo T cell depletion followed by 10/10 HLA-matched UD (66%) or 9/10 UD (34%) graft. Most recipients expressed KIR ligands HLA-C1 (82%) and also HLA-Bw4 (58%). Donor KIR polymorphism reflected the general population: 66% were Bx haplotype and 34% were AA. We found no interactions between KIR/KIR ligand and clinical variables. Multivariate analysis of the impact of donor KIR haplotype (AA vs Bx) and KIR content score showed similar incidence of non-relapse mortality, relapse, acute graftversus-host disease (GVHD), and chronic GVHD and the same leukemia-free survival (LFS) or overall survival rate. All described models showed (prespecified P < .01 to correct for multiple testing) lack of the prognostic value of NK receptor genomics on transplant outcomes. Factors significantly affecting OS included RIC regimen (HR of death .76; P = .05), disease status (non-remission HR 1.96; P = .003), donor type (9/10 UD HR 2.01; P = .0004), Karnofsky score (>80% HR .46; p0.0006), and >3 lines of prior therapy (HR 2.54; p = < .001). Conclusion: Using a large cohort of patients reported to CIBMTR, we demonstrate that donor NK cell KIR/KIR-ligand genetic polymorphisms have no predictive value in CLL alloHCTs supporting the notion that NK cell interactions are specific to the lineage of the underlying leukemia. Background: Human breast milk contains anti-inflammatory proteins and oligosaccharides that maintain infant intestinal homeostasis. We hypothesized that children receiving human milk would have lower plasma inflammatory cytokines and maintain a more diverse stool microbiome after bone marrow transplant (BMT). Methods: Children 0-5 years of age were randomized 2:1 to receive either donor human breast milk formulated specially for the study (Prolacta Bioscience, Duarte, CA) or standard feeding with formula. Both arms were supervised by an expert BMT dietician. Babies who were breastfeeding at the time of BMT were enrolled on the human milk arm without randomization. Human milk was started on day −3 and continued until day +14 after BMT. We observed children for acute graft versus host disease (GVHD) and blood stream infections (BSI) until day +100. Metagenomic shotgun sequencing of stool and plasma cytokine analyses by Luminex were performed for samples at enrollment and day +14 after BMT. Ratios of day +14: baseline cytokines were compared between 2 groups. Results: Forty-two children were enrolled and 23 were randomized to receive human milk while 10 were controls. Nine babies were breastfed at the time of BMT and enrolled to receive maternal milk. Four controls withdrew from study and 2 controls obtained human milk from alternate sources, and were unevaluable. Twenty-four patients received at least 60% of total goal breast milk (determined by enteral feeding volumes or breastfeeding time in minutes), and were included for analysis. We performed an as-treated analysis to assess biological activity of our intervention. Five patients within the human milk group developed engraftment syndrome (n = 4) or sepsis (n = 1) on day +14 and were excluded from cytokine analyses. There were no differences in the median age among the human milk cohort (1.25 years; range .3-4.9 years) and controls (1 year; range .5-1.6 years). All 4 controls and 23/24 of human milk cohort received an allogeneic BMT. Eighteen of the 23 human milk recipients and all 4 controls were unrelated donor transplants. Sixteen human milk recipients and 3 controls were HLA 8/8 matched. IL6, IL8, IL10, IFNγ and SIL2 were decreased in the human milk cohort compared to controls (Figure 1) . Principal coordinate analysis of stool microbiome showed differences in beta diversity in the human milk cohort compared to controls (P = .07) ( Figure 2 ) Specifically, decrease in Streptococcus spp. abundance at day +14 was observed in the human milk cohort compared to controls (P = .04). Four children developed acute GVHD in human milk cohort compared to 3 controls (P = .04). Incidence of blood stream infections was 3/100 line days in the human milk cohort compared to 9/100 line days in controls (P = .09).
Conclusions:
Our data suggest that human milk administration modifies the intestinal microbiome and might reduce inflammation and GVHD (Figure 3 ). 
